GlassScriptPhysician profile
Craig Kunins
NPI 1821158742
$265,423.62
in general payments reported to CMS, 2019-2025
24 companies · $963 in 2025
The $963 reported for 2025 was more than what 85% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96K · 2020: $26K · 2021: $58K · 2022: $45K · 2023: $38K · 2024: $2,421 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $7,993 · Food and Beverage: $3,731 · Consulting Fee: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,775.00 |
| Travel and Lodging | $7,993.24 |
| Food and Beverage | $3,731.04 |
| Consulting Fee | $1,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $140,226.10 | 2019-2024 | Jornay Pm |
| Corium, LLC | $53,508.72 | 2021-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $40,164.22 | 2021-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $18,354.04 | 2019-2021 | |
| Adlon Therapeutics L.P. | $6,750.22 | 2019 | |
| Neos Therapeutics, LP | $2,193.24 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $818.76 | 2019-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $588.03 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $559.29 | 2021-2024 | Caplyta |
| Abbvie INC. | $531.29 | 2021-2023 | |
| Alkermes, INC. | $216.51 | 2023-2024 | Lybalvi |
| Tris Pharma INC | $198.82 | 2025 | Onyda Xr, Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $188.28 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $162.70 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $125.07 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $123.98 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $123.92 | 2025 | Cobenfy |
| Eisai INC. | $123.69 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $121.64 | 2022 | |
| Livanova USA, INC. | $121.43 | 2021 | |
| Allergan, INC. | $116.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $56.54 | 2019-2020 | |
| Rhodes Pharmaceuticals L.P. | $32.15 | 2019 | |
| Shire North American Group INC | $18.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Kunins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.